Skip to content

Annovis Bio, Inc.: 10-Q filed 2025-08-12

What Annovis Bio, Inc. reported in its quarterly report filed 2025-08-12 (fiscal Q2 2025): 26 published measures, 82 facts as tagged in accession 0001558370-25-011233.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-12
Fiscal period
fiscal Q2 2025
Accession
0001558370-25-011233 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Annovis Bio, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3021,454,571USD
At 2024-12-3113,925,633USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-303,124,124USD
At 2024-12-314,617,987USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-3018,330,447USD
At 2025-03-3124,053,887USD
At 2024-12-319,307,646USD
At 2024-06-30-1,750,884USD
At 2024-03-31-3,354,028USD
At 2023-12-31-7,750,846USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-3017,130,286USD
At 2024-12-3110,551,916USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-6,220,058USD91
2025-01-01 to 2025-06-30-11,757,127USD181
2025-01-01 to 2025-03-31-5,537,069USD90
2024-04-01 to 2024-06-30-5,020,412USD91
2024-01-01 to 2024-06-30-6,087,359USD182
2024-01-01 to 2024-03-31-1,066,947USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-13,205,053USD181
2024-01-01 to 2024-06-30-10,407,937USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-3019,783,423USD181
2024-01-01 to 2024-06-308,650,984USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-146,606,589USD
At 2024-12-31-134,849,462USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3019,486,231shares91
2025-01-01 to 2025-06-3018,464,877shares181
2024-04-01 to 2024-06-3011,307,759shares91
2024-01-01 to 2024-06-3010,966,412shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3019,486,231shares91
2025-01-01 to 2025-06-3018,464,877shares181
2024-04-01 to 2024-06-3011,307,759shares91
2024-01-01 to 2024-06-3011,066,265shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.32USD/shares91
2025-01-01 to 2025-06-30-0.64USD/shares181
2024-04-01 to 2024-06-30-0.44USD/shares91
2024-01-01 to 2024-06-30-0.56USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.32USD/shares91
2025-01-01 to 2025-06-30-0.64USD/shares181
2024-04-01 to 2024-06-30-0.44USD/shares91
2024-01-01 to 2024-06-30-1.52USD/shares182

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-300USD181
2024-04-01 to 2024-06-300USD91
2024-01-01 to 2024-06-300USD182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-30996,505USD181
2024-01-01 to 2024-06-301,961,277USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-6,271,453USD91
2025-01-01 to 2025-06-30-12,554,134USD181
2024-04-01 to 2024-06-30-7,762,638USD91
2024-01-01 to 2024-06-30-15,572,445USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-302,805,124USD
At 2024-12-313,880,987USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-06-30974,311USD
At 2024-12-312,305,974USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-306,271,453USD91
2025-01-01 to 2025-06-3012,554,134USD181
2024-04-01 to 2024-06-307,762,638USD91
2024-01-01 to 2024-06-3015,572,445USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-305,161,921USD91
2025-01-01 to 2025-06-3010,173,438USD181
2024-04-01 to 2024-06-305,785,217USD91
2024-01-01 to 2024-06-3012,307,308USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3019,486,231shares
At 2024-12-3114,141,521shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-3017,130,286USD
At 2024-12-3110,551,916USD
At 2024-06-303,997,767USD
At 2023-12-315,754,720USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-30164,935,088USD
At 2024-12-31144,155,694USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-11,757,127USD181
2024-01-01 to 2024-06-30-6,087,359USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,109,532USD91
2025-01-01 to 2025-06-302,380,696USD181
2024-04-01 to 2024-06-301,977,421USD91
2024-01-01 to 2024-06-303,265,137USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-04-01 to 2025-06-3051,395USD91
2025-01-01 to 2025-06-30797,007USD181
2024-04-01 to 2024-06-302,742,226USD91
2024-01-01 to 2024-06-309,485,086USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-1,331,663USD181
2024-01-01 to 2024-06-302,101,820USD182

Inspect the source

Entity
Annovis Bio, Inc. / CIK 0001477845
Captured
2026-09-20T09:08:33.639Z
SEC response SHA-256
5f46431864276f3b86ddd5f520f0f0d740cabb76d1da6c6eaa47ff48ee863f51

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001477845.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))